Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

  • This share is currently suspended. It was suspended at a price of 0.125
  • There is currently no data for CRV

Portfolio Update

3 Mar 2023 18:15

RNS Number : 9177R
Craven House Capital PLC
03 March 2023
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Craven House Capital plc

Portfolio Update

 

Craven House Capital plc ("Craven House" or the "Company"), the AIM quoted investment company provides this update regarding the following investee companies:

Stormfjord Ltd ("Stormfjord")

The Company has been informed that Stormfjord, the owner of www.onebas.com raised $100,000 on 1st March 2023 at a valuation of $28,000,000.

Craven House originally acquired a 29.9% stake in Onebas.com Ltd (the previous legal entity under which the domain Onebas.com was owned) on 13 March 2020 for a consideration of $1,600,000 via a share subscription for 800,000 ordinary shares in the Company priced at $10.00 per share. This valued Onebas.com Ltd at $5.35m.

Following completion of the fundraising, Craven House's holding of 29,900,000 shares represents 25.5% of Stomfjord.

Rosedog Ltd ("Rosedog")

The Company has been informed that Rosedog, the owner of www.tvzinos.com raised $70,000 on 1st March 2023 at a valuation of $28,000,000.

Craven House originally acquired a 29.9% stake in Rosedog on 13 March 2020 for a consideration of $1,600,000 via a share subscription for 800,000 ordinary shares in the Company priced at $10.00 per share. This valued Rosedog Ltd at $5.35m.

Following completion of the fundraising, Craven House's holding of 29,900,000 shares represents 28.6% of Rosedog.

Bio Vitos Ltd ("Bio Vitos")

The Company has been informed that Bio Vitos raised $13,000 on 1st March 2023, at a valuation of $10,000,000.

Craven House originally acquired a 29.9% stake in Bio Vitos (previously called YRRO Ltd) on 13 March 2020 for a consideration of $1,600,000 via a share subscription for 800,000 ordinary shares in the Company priced at $10.00 per share. This valued Bio Vitos at $5.35m.

Following completion of the fundraising, Craven House's holding of 14,708,700 shares represents 24.5% of Bio Vitos.

~ Ends ~

 

For further information please contact:

Craven House Capital Plc

Tel: 0203 286 8130

Mark Pajak

www.Cravenhousecapital.com

Tel: 0203 286 8130

SI Capital

Tel: 01483 413500

Broker

Nick Emerson

www.sicapital.co.uk

SPARK Advisory Partners Limited

Tel: 0203 368 3550

Nominated Adviser

Matt Davis/James Keeshan

www.Sparkadvisorypartners.com

 

About Craven House Capital plc: The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUBIGDXSBGDGXX
Date   Source Headline
30th Sep 20087:00 amRNSInterim Results
8th Sep 200811:00 amRNSProposed cancellation of AIM
4th Sep 200811:37 amRNSResult of AGM
1st Sep 20083:06 pmRNSDirectorate Change
13th Aug 20089:17 amRNSNotice of AGM
4th Jul 200810:47 amRNSDirector/PDMR Shareholding
30th Jun 20084:00 pmRNSAnnual Report and Accounts
30th Jun 20087:00 amRNSFinal Results
30th Apr 200811:03 amRNSUpdate re Report & Accounts
18th Feb 20083:00 pmRNSDirector/PDMR Shareholding
13th Feb 20083:04 pmRNSTrading Statement
23rd Nov 20077:01 amRNSDirectorate Change
28th Sep 20077:05 amRNSInterim Results
26th Sep 20072:00 pmRNSTrading Statement
10th Aug 20077:01 amRNSAIM Rule 26
21st Jun 20077:01 amRNSJoint Venture
19th Jun 20073:52 pmRNSIssue of Warrants
14th Jun 200711:37 amRNSResult of AGM
14th Jun 20077:01 amRNSAGM Statement
31st May 20071:00 pmRNSTotal Voting Rights
31st May 200712:30 pmRNSIssue of Equity
31st May 200712:00 pmRNSRelated Party Transactions
25th Apr 20072:42 pmRNSTrading Update
11th Apr 200711:20 amRNSHolding(s) in Company
22nd Mar 20077:02 amRNSFinal Results
19th Mar 20078:00 amRNSNotice of Results
11th Dec 200611:51 amRNSTotal Voting Rights
26th Oct 20067:01 amRNSProperty Development
27th Sep 20067:01 amRNSInterim Results
31st Jul 20067:01 amRNSSaga Contract
10th Jul 20067:00 amRNSItalian Contract Update
4th Jul 200610:58 amRNSChange of Adviser
16th Jun 20064:13 pmRNSResult of AGM
16th Jun 20067:00 amRNSAGM Statement
17th May 20067:00 amRNSReport and Accounts Posted
25th Apr 20062:48 pmRNSProgress in First Quarter
6th Apr 20066:24 pmRNSDirector/PDMR Shareholding
6th Apr 20068:00 amRNSPreliminary Results
22nd Feb 20063:46 pmRNSShare price movement
16th Dec 200512:25 pmRNSChange of Registered Office
23rd Nov 20057:00 amRNSExpansion into Cyprus, Turkey
28th Oct 20058:00 amRNSBusiness Update
29th Sep 20054:47 pmRNSInterim Results
4th Jul 20057:00 amRNSProperty Development
15th Jun 200511:00 amRNSAGM Statement
20th May 200512:59 pmRNSAnnual Report and Accounts
16th May 20059:00 amRNSBusiness Update
21st Apr 200512:42 pmRNSTrading Statement
21st Mar 20059:38 amRNSFinal Results
3rd Mar 20054:39 pmRNSNotice of Prelimnary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.